Read by QxMD icon Read

Journal of Child and Adolescent Psychopharmacology

Laura B Ramsey, Stacey L Aldrich, Ethan Poweleit, Cynthia A Prows, Lisa J Martin, Jeffrey R Strawn
No abstract text is available yet for this article.
November 14, 2018: Journal of Child and Adolescent Psychopharmacology
Nils C Westfall, Nicole A Mavrides, Barbara J Coffey
No abstract text is available yet for this article.
November 14, 2018: Journal of Child and Adolescent Psychopharmacology
Harold S Koplewicz
No abstract text is available yet for this article.
November 14, 2018: Journal of Child and Adolescent Psychopharmacology
Marie Raffin, Olivier Bonnot, Marianna Giannitelli, Jean Xavier, Nicolas Bodeau, Barbara Bibrac, Monique Leban, Bruno Fautrel, Marie-Line Menard, Angele Consoli, David Cohen
OBJECTIVES: Osteoporosis is a major risk factor for fracture and treatment is mainly preventive. Patients with severe psychiatric condition and treated with antipsychotics are at risk for vitamin D deficiency and iatrogenic hyperprolactinemia, two serious risk factors of osteoporosis. We aim to determine whether all antipsychotics are similar regarding the risk of osteoporosis in young patients. METHODS: From January 2009 to March 2015, we determined the vitamin D blood level (VDBL) among 484 inpatients and from January 2012 to March 2015, we determined the prolactin blood level (PBL) among 205 inpatients...
November 13, 2018: Journal of Child and Adolescent Psychopharmacology
Collin Leibold, Margo Thienemann, Bahare Farhadian, Theresa Willett, Jennifer Frankovich
OBJECTIVES: This study validates the caregiver-rated Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Global Impairment Score (GIS), a single-item, 0-100 scale, for use in PANS. METHODS: We collected longitudinal data from community patients meeting PANS criteria. We included 128 patients with 1926 GISs, each from a unique clinic visit. To assess discriminant validity, we compared GISs from patients with PANS with scores from a population of healthy controls...
November 13, 2018: Journal of Child and Adolescent Psychopharmacology
Aiswarya Laks Nandakumar, Jennifer L Vande Voort, Paul A Nakonezny, Scott S Orth, Magdalena Romanowicz, Ayse Irem Sonmez, Jessica A Ward, Sandra J Rackley, John E Huxsahl, Paul E Croarkin
OBJECTIVES: The Patient Health Questionnaire-9 Modified (PHQ-9M) is a self-report tool used to assess the presence and severity of depressive symptoms in teenagers. Despite widespread use in primary care clinics and psychiatric settings, the PHQ-9M has not been validated nor are its psychometric properties adequately understood for the adolescent population. This study sought to examine the psychometrics of the PHQ-9M in treatment-seeking, depressed adolescents at a psychiatric psychopharmacology clinic who were concurrently assessed with the Children's Depression Rating Scale Revised (CDRS-R) and Quick Inventory of Depressive Symptomatology-Adolescent (17-item) Self-Report (QIDS-A17-SR)...
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Diane Hurd, Mariela Herrera, Jeannine M Brant, Nicholas C Coombs, Eric Arzubi
OBJECTIVE: The aim of this pilot study was to explore the feasibility and proof of concept of triple chronotherapy (TCT) as a nonpharmacological adjunctive treatment in the acute management of depression in the adolescent population. METHODS: Thirty-one adolescents with nonpsychotic moderate-to-severe depression were included in the study. The 4-day TCT intervention comprised one night of sleep deprivation followed by 3 days of sleep phase advancement and daily bright light therapy...
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Kirsi Kakko, Nina Bjelogrlic-Laakso, Leena Pihlakoski, Kai Lehtimäki, Kaija Järventausta
No abstract text is available yet for this article.
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Tayfun Kara, Ajda Mutlu Mıhçıoğlu, Semra Yılmaz, İsmail Akaltun
OBJECTIVE: Many children diagnosed with attention-deficit/hyperactivity disorder are treated with methylphenidate (MPH). The purpose of this study was to evaluate the relationship between long-term use of osmotic-release oral system methylphenidate (OROS MPH) and cardiac functions. METHODS: The study involved 116 subjects 6-18 years of age. Fifty-eight of these were in the case group and were using OROS MPH (extended-release capsules). Fifty-eight children not receiving treatment were included in the control group...
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Ann C Childress, Jeffrey G Stark
OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder defined as a persistent pattern of inactivity and/or hyperactivity that interferes with behavioral function or development. Diagnosis and treatment of ADHD in the preschool-aged population (children 3-5 years old) is more complicated compared with older children because of developmental and physiological differences. This article reviews the available literature regarding the challenges associated with ADHD diagnosis and treatment in preschool-aged children, as well as the unmet needs of preschool-aged children with ADHD...
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Pei-Yin Pan, Chin-Bin Yeh
OBJECTIVES: Irritability is among the most bothersome emotional symptoms in children. It often leads to mental health services referral, significant impairment, and distress to their families. Although there is increasing scientific evidence supporting the existence of extreme irritability in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5) diagnosis of disruptive mood dysregulation disorder, few studies have investigated the measurement of irritability in children...
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Emily J Ricketts, Alexandra Sturm, Dana L McMakin, Joseph F McGuire, Patricia Z Tan, Fallon B Smalberg, James T McCracken, Christopher S Colwell, John Piacentini
OBJECTIVE: Stimulant medication and behavior therapy are efficacious for youth with attention-deficit/hyperactivity disorder (ADHD). However, research suggests that stimulants may start and/or worsen sleep problems for youth. Further, the impact of behavior therapy for ADHD on sleep is unknown. This study examined the frequency of sleep problems and effects of stimulant medication, behavior therapy, and their combination on sleep problems in youth with ADHD. This study also explored the influence of dimensional baseline ratings of ADHD symptom subtype and psychiatric comorbidity on sleep outcomes...
November 2, 2018: Journal of Child and Adolescent Psychopharmacology
Simina Toma, Alvi H Islam, Arron W S Metcalfe, Rachel H B Mitchell, Lisa Fiksenbaum, Bradley J MacIntosh, Benjamin I Goldstein
OBJECTIVES: Neuroimaging studies of adults with bipolar disorder (BD) have identified several BD subtype distinctions, including greater deficits in prefrontal gray matter volumes in BD-I (bipolar I disorder) compared to BD-II (bipolar II disorder). We sought to investigate BD subtype differences in brain structure among adolescents and young adults. METHODS: Forty-four youth with BD (14 BD-I, 16 BD-II, and 14 BD-not otherwise specified [NOS], mean age 17) underwent 3T-MRI and images were analyzed using FreeSurfer software...
October 25, 2018: Journal of Child and Adolescent Psychopharmacology
Laura M Steinauer, Jonathan G Leung, Betsy Walters Burkey, Ian R McGrane, Victoria Letts, Jessica L Goren, Dawn M Hoeft, Sandra Mullen, Megan Maroney, Kathryn M Schak, Jennifer L Vande Voort
OBJECTIVES: Clozapine is the drug of choice for treatment-resistant schizophrenia. While pediatric clozapine use is not contraindicated, the literature describing its clinical application is limited. The primary objective of this study was to assess the use of clozapine in a child and adolescent population by characterizing the documented safety and clinical benefits of the medication. METHODS: A multicenter retrospective study at sites in the United States and Australia included children and adolescents admitted to a psychiatric unit who were administered at least one dose of clozapine...
October 24, 2018: Journal of Child and Adolescent Psychopharmacology
Daniel Boloc, Sergi Mas, Natalia Rodriguez, Ana E Ortiz, Astrid Morer, Maria Teresa Plana, Amalia Lafuente, Luisa Lazaro, Patricia Gassó
OBJECTIVE: Obsessive-compulsive disorder (OCD) is a debilitating neuropsychiatric disorder whose etiology includes important genetic contributions. In a previous transmission disequilibrium study in which 75 complete trios were included, single-nucleotide polymorphisms (SNPs) in serotoninergic and GABAergic genes were associated with early-onset OCD. Our aim was to assess those findings in an extended collection of early-onset OCD trios. METHODS: A transmission disequilibrium test for SNPs in HTR1B (rs2000292), SLC18A1 (rs6586896), GAD1 (rs3791860), and GAD2 (rs8190748) was performed in a total of 101 early-onset OCD trios, from which 26 trios were newly recruited for the purpose of the present analysis...
October 23, 2018: Journal of Child and Adolescent Psychopharmacology
Esther S Lee, Carol Vidal, Robert L Findling
OBJECTIVES: The use of atypical antipsychotic medications in pediatric patients has become more prevalent in recent years. The purpose of this review is to provide a clinically relevant update of recent selected key publications regarding the use of atypical antipsychotics in this population. METHODS: Studies reviewed included randomized, double-blind, placebo-controlled medication trials conducted within the past 5 years. A PubMed search was conducted for each of the 11 second-generation antipsychotic medications currently approved by the Food and Drug Administration for use in the United States: clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, paliperidone, asenapine, iloperidone, lurasidone, and cariprazine...
October 12, 2018: Journal of Child and Adolescent Psychopharmacology
Larissa Niemeyer, Lucca Schumm, Konstantin Mechler, Christine Jennen-Steinmetz, Ralf W Dittmann, Alexander Häge
OBJECTIVES: Medication nonadherence constitutes a major problem in adolescent psychiatry. Previous studies have identified various factors associated with nonadherent behavior. The aim of this study is to explore adolescents' health beliefs and subjective perceptions relating to psychotropic medication, and to statistically link these to reported medication adherence. METHODS: The findings presented in this study are part of the multicenter SEMA study (Subjective Experience and Medication Adherence in Adolescents with Psychiatric Disorders)...
August 27, 2018: Journal of Child and Adolescent Psychopharmacology
Sarah A Orban, Tanya A Karamchandani, Leanne Tamm, Craig A Sidol, James Peugh, Tanya E Froehlich, William B Brinkman, Nicole Estell, Akemi E Mii, Jeffery N Epstein
OBJECTIVE: We aimed to (1) examine differences in observed visual attention and motor activity, as well as comprehension of a science video between children with and without attention-deficit/hyperactivity disorder (ADHD) and (2) explore if psychostimulant medication improves ADHD behaviors and comprehension of a science video in children with ADHD. METHOD: Children aged 7-11 with (n = 91) and without (n = 45) ADHD watched a science video and then completed a comprehension test...
August 27, 2018: Journal of Child and Adolescent Psychopharmacology
Pei-Yin Pan, An-Ting Fu, Chin-Bin Yeh
OBJECTIVES: Disruptive mood dysregulation disorder (DMDD) is characterized by nonepisodic irritability and has a high rate of comorbidity with attention-deficit/hyperactivity disorder (ADHD). This is the first study to explore the effects of aripiprazole combined with methylphenidate on clinical symptoms and cognitive functions in patients with DMDD and ADHD. METHODS: Patients with DMDD and ADHD (the DMDD-ADHD Group, n = 24; aged 7-17 years) completed a 6-week, open-label trial of aripiprazole and methylphenidate...
August 27, 2018: Journal of Child and Adolescent Psychopharmacology
Athanasios Maras, Carmen M Schroder, Beth A Malow, Robert L Findling, John Breddy, Tali Nir, Shiri Shahmoon, Nava Zisapel, Paul Gringras
OBJECTIVE: A recent double-blind randomized placebo-controlled study demonstrated 3-month efficacy and safety of a novel pediatric-appropriate prolonged-release melatonin (PedPRM) for insomnia in children and adolescents with autism spectrum disorder (ASD) and neurogenetic disorders (NGD) with/without attention-deficit/hyperactivity disorder comorbidity. Long-term efficacy and safety of PedPRM treatment was studied. METHODS: A prospective, open-label efficacy and safety follow-up of nightly 2, 5, or 10 mg PedPRM in subjects who completed the 13-week double-blind trial (51 PedPRM; 44 placebo)...
August 22, 2018: Journal of Child and Adolescent Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"